Pacer Advisors
CERE

Pacer Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Pacer Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,043
Closed -$42.6K – 2721
2024
Q2 		$42.6K Buy
1,043
+8
+0.8% +$333 ﹤0.01% 3247
2024
Q1 		$43.7K Buy
+1,035
New +$43.5K ﹤0.01% 3222
2021
Q2 		– Sell
-1,444
Closed -$20K – 1576
2021
Q1 		$20K Buy
+1,444
New +$21.1K ﹤0.01% 1506

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Pacer Advisors's CERE Position: Q3 2024 in Review

Pacer Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 1,043 shares — an estimated $42.6K sold.

Pacer Advisors first reported a position in CERE in Q1 2021 and held it in 3 quarters. The position peaked at $43.7K in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Pacer Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,043 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $42.6K.
  • Pacer Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Pacer Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $43.7K in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.